Nasdaq:US$15.08 (-0.94) | HKEX:HK$23.52 (-1.22) | AIM:£2.36 (+0.04)
Search
Announcements
1
23456789101112131415161718
found Documents: 861
Announcements & Press Releases, Oncology / Immunology | 13 Oct 2025

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
— The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies —   Hong Kong, Shanghai & Florham Park, NJ — Monday, Octob
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Oct 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 2 Oct 2025

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED wil
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2025

Total Voting Rights
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Sep 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —   Hong Kong, Shanghai & Florham Park, NJ —   Friday, September 12, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Sep 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
Hong Kong, Shanghai & Florham Park, NJ — Friday, September 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED wil
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Sep 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 25 Aug 2025

List of Directors and Their Roles and Functions
The Board of Directors of HUTCHMED (China) Limited comprises 9 Directors as follows: Chairman and Non-executive Director Dr Dan ELDAR Executive Directors Dr Weiguo SU (Chief Executive Officer* and Chief Scientific Officer) Mr CHENG Chig Fung
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 25 Aug 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 25, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence f
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Interim Reports, Regulatory Notice | 22 Aug 2025

Interim Report 2025
Notification letter to non-registered shareholders and request form: Notice of Publication of 2025 Interim ReportNotification letter to registered shareholders and request form: Notice of Publication of 2025 Interim Report2025 Interim Report2025 Interim Report (Chinese version)
Announcements & Press Releases, Oncology / Immunology | 20 Aug 2025

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Hong Kong, Shanghai & Florham Park, NJ —  Wednesday, August 20, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHY
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 7 Aug 2025

HUTCHMED Reports 2025 Interim Results
— Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal —   Hong Kong, Shanghai & Florham Park, NJ — Thursday, A
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Aug 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2025

HUTCHMED to Announce 2025 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 3, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2025

Update on Joint Corporate Brokers in London
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deutsche Bank AG (trading as Deutsche Numis) as its joint Corporate Brok
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2025

Total Voting Rights
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2025

Blocklisting Six Monthly Return
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Jun 2025

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consisten
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Jun 2025

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 10, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 9, 2025, it granted share options (“Share Options”) under the Share Option Scheme ad
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Jun 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Appl
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jun 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 2 Jun 2025

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —   — Webcast to be held at 8:30 am HKT on Tuesday, June 3 t
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 May 2025

Total Voting Rights
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 30, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at May 30, 2025, the issued share capital of HUTCHMED consisted of 871,6
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 May 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 23, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitini
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 May 2025

List of Directors and Their Roles and Functions
The Board of Directors of HUTCHMED (China) Limited comprises 9 Directors as follows: Chairman and Non-executive Director Dr Dan ELDAR Executive Directors Dr Weiguo SU (Chief Executive Officer and Chief Scientific Officer) Mr CHENG Chig Fung,
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 May 2025

Annual General Meeting held on May 13, 2025 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 13, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual Gener
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Apr 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 24, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED incl
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 Apr 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 22, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savo
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 7 Apr 2025

Annual General Meeting 2025
Date: Tuesday, May 13, 2025 Time: 4pm Hong Kong Time (9am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  
Read More
2024 Annual Report (PDF)2024 Sustainability Report (PDF)Circular - Annual General Meeting (PDF)Announcement - Notice of Annual General Meeting (PDF)Form of Proxy (PDF)Notification letter to registered holders and request form (PDF)Notification letter to non-registered holders and request form (PDF)Online AGM User Guide (PDF)
Announcements & Press Releases, Regulatory Notice | 7 Apr 2025

2024 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 7, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2024 Annual Report, together with the Notice of Annual General Meeting and the Form
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)HKEX Announcement – Notice of Annual General Meeting (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Apr 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Mar 2025

Extraordinary General Meeting held on March 31, 2025 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary resolution put to its Extraordinary General Meeting (“E
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Mar 2025

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
— First and only EZH2 inhibitor approved by the NMPA —   —HUTCHMED’s fourth product, and its first approval in hematological malignancies —   Hong Kong, Shanghai & Florham Park, NJ — Friday, March 21, 2025: HUTCHMED (C
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Mar 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
Hong Kong, Shanghai & Florham Park, NJ  — Thursday, March 20, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who hav
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Mar 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 19 Mar 2025

OVERSEAS REGULATORY ANNOUNCEMENT: Publication of Form 20-F
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 19 Mar 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
65% oncology products revenue growth drove profitable operation and supported new ATTC platform   Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Mar 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Mar 2025

Adoption of the 2025 Long Term Incentive Plan
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from a voluntary announcement released to the Stock Exchange of Hong Kong Limited on March 14, 2025. The text relates to the adoption of the 2025 Long Term Incentive Plan with e
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Mar 2025

Vesting of Awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 14, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Mar
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 13 Mar 2025

Extraordinary General Meeting (March 31, 2025)
  Date:  Monday, March 31, 2025 Time:  3:00 pm Hong Kong Time (8:00 am London Time) Location:  47th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong Online: https://meetings.computershare.com/Hutchmed2
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory AnnouncementCircular - Extraordinary General MeetingAnnouncement - Notice of Extraordinary General MeetingForm of ProxyNotification letter to registered holders and request formNotification letter to non-registered holders and request formEGM online user guide
Announcements & Press Releases, Regulatory Notice | 6 Mar 2025

List of Directors and Role and Function
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Mar 2025

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
Hong Kong, Shanghai & Florham Park, NJ —  Thursday, March 6, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)  today announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453)
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 5 Mar 2025

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 5, 2025: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independen
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Mar 2025

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Mar 2025

Overseas Regulatory Announcement – Update on Transaction
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on March 2, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Ex
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Feb 2025

Overseas Regulatory Announcement – Update on Transaction
HUTCHMED (China) Limited (“HUTCHMED”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on February 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stoc
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 19 Feb 2025

HUTCHMED to Announce 2024 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
1
23456789101112131415161718